Published On: June 6th, 2016

Scientists and Engineers have developed a continuous production version of Greenovation`s moss-based manufacturing technology for biopharmaceuticals (BryoTechnology). Now established in small-scale research fermentations, the process delivers valuable data for further scale-up and continuous production with moss under GMP. The current process is designed for a 3.5 L stirred tank bioreactor with a fixed media exchange-rate and allows a continuous harvest of the culture broth. Constant cell density results in a controlled and effective illumination of the photo bioreactor. Current tests over four weeks revealed a perfectly stable process. Future tests will focus on monitoring product quality under varying process parameters to gain a firm understanding of critical conditions and define edges of failure.

“Continuous processes bring several advantages for biopharmaceutical production” says Dr. Frischmuth, CEO of Greenovation. “Not only do they save time and money and therefore offer our clients a faster time to market for their products. Furthermore, continuous process design allows for the constant harvest and immediate processing of potentially instable biopharmaceuticals. As such products might degrade in batch-based production, continuous process design offers a perfect solution here.”

About Greenovation Biotech GmbH

Greenovation develops next-generation therapeutics using its proprietary BryoTechnology platform. The company aims to optimize the production of highly-efficient glycoproteins for the treatment of rare diseases. BryoTechnology is available for contract development and licensing. Greenovation is a privately owned biopharmaceutical company based in Heilbronn, Germany. It was founded in 1999 by Prof. Dr. Ralf Reski and Prof. Dr. Gunter Neuhaus. Today, Greenovation Biotech GmbH is majority-owned by Zukunftsfonds Heilbronn and L-EigenkapitalAgentur (Karlsruhe).